Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 13/20 | 0.54 |
| ▸ | F13A1 | P00488 | 10/20 | 0.54 |
| ▸ | TGM1 | P22735 | 7/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | TGM3 | Q08188 | 1/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2378926 | 0.86 | TGM2 (0.56) | TGM2F13A1TGM1PKMGPR119 | |
| SCHEMBL31165481 | 0.86 | TGM2 (0.56) | TGM2F13A1TGM1PKMGPR119 | |
| SCHEMBL2376710 | 0.85 | ABL1 (0.59) | TGM2F13A1TGM1 | |
| SCHEMBL14490217 | 0.83 | TGM2 (0.53) | TGM2F13A1TGM1PKMHSD17B10 | |
| SCHEMBL14490221 | 0.81 | ABL1 (0.55) | TGM2F13A1TGM1PKMHSD17B10 | |
| SCHEMBL18498875 | 0.81 | TGM2 (0.53) | TGM2F13A1TGM1TGM3GPR119 | |
| SCHEMBL309243 | 0.81 | TGM2 (0.64) | TGM2F13A1TGM1PKMGPR119 | |
| SCHEMBL5442261 | 0.81 | TGM2 (0.52) | TGM2F13A1TGM1TGM3GPR119 | |
| SCHEMBL309691 | 0.81 | EPHX2 (0.55) | TGM2F13A1TGM1TGM3GPR119 | |
| SCHEMBL710366 | 0.81 | TGM2 (0.64) | TGM2F13A1TGM1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007056075-A2 | SIX MEMBERED HETEROAROMATIC INHIBITORS TARGETING RESISTANT KINASE MUTATIONS | TARGEGEN, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056075-A2 | SIX MEMBERED HETEROAROMATIC INHIBITORS TARGETING RESISTANT KINASE MUTATIONS | TARGEGEN, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | ABL1, KDR, BCR | TGM2 1975/4885F13A1 4382/4885TGM1 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.